Combating Illicit Xylazine Act

The Combating Illicit Xylazine Act proposes to address the rising use of xylazine—a powerful veterinary sedative often called "tranq"—in the illegal drug market. The bill would classify xylazine as a Schedule III controlled substance under the Controlled Substances Act. This change would give the Drug Enforcement Administration (DEA) and local law enforcement stronger tools to track the drug’s manufacturing, penalize illegal traffickers, and prevent it from being mixed with opioids like fentanyl.

Because xylazine is not an opioid, its effects cannot be reversed by naloxone (Narcan), making overdoses involving the drug particularly dangerous. To combat this, the legislation would require federal reports on the drug’s prevalence and health risks. It also aims to protect the legitimate use of the medication for animals by ensuring that veterinarians, farmers, and ranchers can still legally obtain and use it for its intended purpose without facing new criminal penalties for lawful possession.

If enacted, the bill would increase federal oversight of the xylazine supply chain to disrupt the networks distributing it for human consumption. For everyday citizens, this means law enforcement would have more authority to target the sale of "tranq" on the streets, while agricultural and veterinary professionals would maintain access to a critical tool for animal care under specific regulatory safeguards.